Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Trioar is a platform company developing next-generation antibody-based technologies to improve the efficacy and therapeutic index of antibody-based therapeutics, including enhanced ADC (antibody-drug conjugate) options. The company focuses on immuno-oncology and cell-targeting therapies for patients with tumors.
2 investors
TriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
2 investors
Trisk Bio develops scalable preclinical manufacturing processes for AAV (adeno-associated virus) gene therapies, offering bespoke production, purification, and process optimization services. It serves gene therapy developers and preclinical research teams in the biotech industry.
2 investors
Triton Therapeutics is a clinical-stage biotechnology company developing first-in-class medicines for autoimmune and fibrotic diseases.
2 investors
Trogenix develops precision genetic medicines for cancer treatment using proprietary Synthetic Super-Enhancers technology delivered via AAV vectors, targeting solid tumors with personalized in situ vaccinations. The company focuses on oncology with applications in regenerative medicine, beginning with glioblastoma.
2 investors
SPT Labtech designs and manufactures laboratory instruments and automation tools for life science research, including liquid handling systems, cryo-electron microscopy sample preparation, and automated sample storage. Its products serve scientists and researchers in genomics, protein crystallization, drug discovery, and next generation sequencing.
2 investors
Tybrhealth develops the B3 GEL™ System, a protective gel applied during tendon and ligament repair surgery to reduce post-operative scar formation and preserve tissue mobility. The product is marketed to surgeons seeking to improve functional outcomes for patients recovering from tendon repair procedures.
2 investors
Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies. Its lead program is a CDK2 inhibitor (CDK2i), with plans to expand into additional kinase targets across the human kinome.
2 investors
U-Ploid develops therapeutic treatments to address age-related infertility by preventing chromosome errors in eggs during IVF procedures. The company targets individuals and healthcare providers seeking effective reproductive health solutions for later-life family planning.
2 investors
Ultragenyx is a biotechnology company focused on developing treatments for patients living with rare genetic diseases. The company emphasizes a culture of generosity, curiosity, and inclusion among its team members.
2 investors
uMed provides data and insights infrastructure to accelerate the development and delivery of new medicines by addressing evidence gaps across the therapy lifecycle. The company enables access to clinical research data and patient insights for pharmaceutical companies, researchers, and healthcare institutions developing new treatments.
2 investors
Uncommon Therapeutics uses advanced technologies to develop drugs targeting rare genetic diseases, starting with Rett Syndrome, a neurodevelopmental disorder affecting approximately 1 in 10,000 girls. The company combines disease expertise with efficient drug development to advance therapeutics from discovery to clinical application.
2 investors
Unibaio develops TurboCharge, a bioactive carrier platform that makes existing crop protection products more effective, allowing lower chemical use while improving field performance for farmers. The technology draws on biological and materials science to deliver agrochemicals and biologicals across a range of crops.
2 investors
The company builds technology focused on improving patient outcomes in healthcare.
2 investors
Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation. It runs a discovery organization in Boulder, Colorado, aiming to create treatments for patients with unmet medical needs.
2 investors
UrbanKisaan develops machine learning models and hardware systems for accelerated plant breeding. The company creates foundation models that predict plant traits from genetic sequences and environmental data, paired with controlled-environment chambers that compress traditional multi-year breeding cycles into months by enabling rapid generations and continuous phenotype data collection.
2 investors
Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments. The company is led by scientists and clinicians focused on creating therapeutic options for patients with underserved rare diseases.
2 investors
2 investors
Valinor Discovery generates patient-derived datasets combining multi-omics and clinical data to enable machine learning applications in drug development. The company collects longitudinal data across molecular and imaging assays to create virtual patient profiles for pharmaceutical research.
2 investors
VaxcellBio develops anti-cancer immunotherapies, including NK cell therapies, CAR cell therapies, targeted anti-cancer agents, and antibody treatments for cancers such as liver, small-cell lung, pancreatic, solid, and blood cancers. It also develops immuno-oncology products for companion animals, including treatments for mammary tumors and lymphoma.
2 investors
2 investors
Vedere Bio develops optogenetics-based gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA), using proprietary AAV vectors for intravitreal administration to restore vision in visually impaired patients globally.
2 investors
Vensica is a clinical-stage medical company developing ViXe, a needle-free treatment for overactive bladder that combines the neurotoxin Xeomin with Vibe, an ultrasound-based drug delivery device that microinjects medication into the bladder wall. The company focuses on urology therapeutics for unmet medical needs.
2 investors
Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs. Its tests analyze each patient's tumor biology to help clinicians make personalized treatment decisions.
2 investors